Aarey Drugs Pharmaceuticals Stock Current Valuation
| AAREYDRUGS | 35.74 0.94 2.56% |
Valuation analysis of Aarey Drugs Pharmace helps investors to measure Aarey Drugs' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. At this time, Aarey Drugs' Cash is relatively stable compared to the past year. As of 03/27/2025, Cash And Short Term Investments is likely to grow to about 34.9 M, while Other Cashflows From Financing Activities is likely to drop (16 M). Fundamental drivers impacting Aarey Drugs' valuation include:
Price Book 0.767 | Enterprise Value 1.4 B | Enterprise Value Ebitda 10.9237 | Price Sales 0.1776 | Trailing PE 16.9384 |
Fairly Valued
Today
Please note that Aarey Drugs' price fluctuation is very steady at this time. Calculation of the real value of Aarey Drugs Pharmace is based on 3 months time horizon. Increasing Aarey Drugs' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Aarey stock is determined by what a typical buyer is willing to pay for full or partial control of Aarey Drugs Pharmaceuticals. Since Aarey Drugs is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Aarey Stock. However, Aarey Drugs' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 35.74 | Real 34.45 | Hype 34.87 | Naive 38.97 |
The intrinsic value of Aarey Drugs' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Aarey Drugs' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Aarey Drugs Pharmaceuticals helps investors to forecast how Aarey stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Aarey Drugs more accurately as focusing exclusively on Aarey Drugs' fundamentals will not take into account other important factors: Aarey Drugs Pharmaceuticals Company Current Valuation Analysis
Aarey Drugs' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Aarey Drugs Current Valuation | 1.42 B |
Most of Aarey Drugs' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Aarey Drugs Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Aarey Drugs Pharmaceuticals has a Current Valuation of 1.42 B. This is 90.1% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The current valuation for all India stocks is 91.45% higher than that of the company.
Aarey Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Aarey Drugs' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Aarey Drugs could also be used in its relative valuation, which is a method of valuing Aarey Drugs by comparing valuation metrics of similar companies.Aarey Drugs is currently under evaluation in current valuation category among its peers.
Aarey Fundamentals
| Return On Equity | 0.0472 | ||||
| Return On Asset | 0.0108 | ||||
| Profit Margin | 0.01 % | ||||
| Operating Margin | 0.01 % | ||||
| Current Valuation | 1.42 B | ||||
| Shares Outstanding | 28.35 M | ||||
| Shares Owned By Insiders | 50.49 % | ||||
| Shares Owned By Institutions | 2.34 % | ||||
| Price To Book | 0.77 X | ||||
| Price To Sales | 0.18 X | ||||
| Revenue | 3.96 B | ||||
| Gross Profit | 172.17 M | ||||
| EBITDA | 114.16 M | ||||
| Net Income | 46.84 M | ||||
| Total Debt | 313.52 M | ||||
| Book Value Per Share | 48.33 X | ||||
| Cash Flow From Operations | (29.94 M) | ||||
| Earnings Per Share | 2.11 X | ||||
| Beta | 0.8 | ||||
| Market Capitalization | 1.02 B | ||||
| Total Asset | 3.03 B | ||||
| Retained Earnings | 531.08 M | ||||
| Working Capital | 1.14 B | ||||
| Net Asset | 3.03 B |
About Aarey Drugs Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Aarey Drugs Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aarey Drugs using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aarey Drugs Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for Aarey Stock Analysis
When running Aarey Drugs' price analysis, check to measure Aarey Drugs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aarey Drugs is operating at the current time. Most of Aarey Drugs' value examination focuses on studying past and present price action to predict the probability of Aarey Drugs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aarey Drugs' price. Additionally, you may evaluate how the addition of Aarey Drugs to your portfolios can decrease your overall portfolio volatility.